Abstract
Platelet aggregation, and activation of coagulation cascade are the key events in the development of acute coronary syndromes (ACS). Patients with this syndrome are at high risk of adverse events, such as death and myocardial infarction (MI). Optimized medical treatment for the non-ST segment elevation ACSs should consist of a combined antithrombotic / anti-anginal regimen. Standard anti-thrombotic treatment is currently unfractionated heparin (UH) and aspirin, and in high-risk patients glycoprotein IIb / IIIa inhibitors. UH has been shown to reduce the risk of death or myocardial infarction in aspirin-treated patients with ACSs, but it has a number of limitations, such as need for regular monitoring and the risk of hemorrhage and thrombocytopenia. Compared to UH, the low molecular weight heparins (LMWH) possess several important theoretical advantages for the treatment of patients with ACSs, including less non-specific binding, resistance to inactivation by platelet factor-4, more reliable anticoagulation effects, and greater factor anti-Xa activity. Recently published trials strongly support the use of LMWHs in the treatment of ACSs. These agents provide an alternative to UH that is at least as effective. The available evidence favours the use of these agents in acute cardiac care. This article explores the recent clinical data on the use of LMWHs in acute cardiac care, and looks critically at the differences between traditional therapies. Recommendations regarding the use of anti-thrombotic agents in patients with ACSs are also discussed.
Keywords: acute coronary syndromes, low-molecular weight heparins, unfractionated heparin
Current Vascular Pharmacology
Title: Low-Molecular-Weight Heparins in Acute Coronary Syndromes
Volume: 1 Issue: 3
Author(s): Mehmet E. Korkmaz
Affiliation:
Keywords: acute coronary syndromes, low-molecular weight heparins, unfractionated heparin
Abstract: Platelet aggregation, and activation of coagulation cascade are the key events in the development of acute coronary syndromes (ACS). Patients with this syndrome are at high risk of adverse events, such as death and myocardial infarction (MI). Optimized medical treatment for the non-ST segment elevation ACSs should consist of a combined antithrombotic / anti-anginal regimen. Standard anti-thrombotic treatment is currently unfractionated heparin (UH) and aspirin, and in high-risk patients glycoprotein IIb / IIIa inhibitors. UH has been shown to reduce the risk of death or myocardial infarction in aspirin-treated patients with ACSs, but it has a number of limitations, such as need for regular monitoring and the risk of hemorrhage and thrombocytopenia. Compared to UH, the low molecular weight heparins (LMWH) possess several important theoretical advantages for the treatment of patients with ACSs, including less non-specific binding, resistance to inactivation by platelet factor-4, more reliable anticoagulation effects, and greater factor anti-Xa activity. Recently published trials strongly support the use of LMWHs in the treatment of ACSs. These agents provide an alternative to UH that is at least as effective. The available evidence favours the use of these agents in acute cardiac care. This article explores the recent clinical data on the use of LMWHs in acute cardiac care, and looks critically at the differences between traditional therapies. Recommendations regarding the use of anti-thrombotic agents in patients with ACSs are also discussed.
Export Options
About this article
Cite this article as:
Korkmaz E. Mehmet, Low-Molecular-Weight Heparins in Acute Coronary Syndromes, Current Vascular Pharmacology 2003; 1 (3) . https://dx.doi.org/10.2174/1570161033476574
DOI https://dx.doi.org/10.2174/1570161033476574 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
LGE-MRI in the Assessment of Left-ventricular Remodelling in Myocarditis
Current Medical Imaging Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders Cardiovascular Morbidity and Mortality in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial (Thematic Issue: Oxidative Stress as a Pharmacological Target for Medicinal Chemistry: Synthesis and Evaluation of Compounds with Redox Activity - Part 3)
Current Topics in Medicinal Chemistry Critical Limb Ischemia: Definition and Natural History
Current Drug Targets - Cardiovascular & Hematological Disorders Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of Disability in Peripheral Arterial Disease: New Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Ceramide Trihexoside (Globotriaosylceramide) in the Diagnosis and Follow-Up of the Efficacy of Treatment of Fabry Disease: A Review of the Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Endothelial Cell Function in Utero-placental Circulation Physiology and Pathophysiology
Current Vascular Pharmacology Pharmacophore-based Screening for Identification of Human Acyl-CoA Cholesterol Acyltransferase Inhibitors: An In-silico Study
Letters in Drug Design & Discovery A Hybrid Approach for Sub-Acute Ischemic Stroke Lesion Segmentation Using Random Decision Forest and Gravitational Search Algorithm
Current Medical Imaging 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology Editorial (Thematic Issue: Molecular and Cellular Engineering Approaches for Neurological Disorders, Diseases, and Injuries Involved the Central and Peripheral Nervous Systems)
CNS & Neurological Disorders - Drug Targets Renin-Angiotensin-Aldosterone System in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology